ArticleBioinformatics (Oxford, England)2026
FourierDrug: a domain generalization framework for robust drug response prediction via frequency-space asymmetric attention.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationAccurate prediction of drug response remains a major challenge in precision oncology, particularly at the single-cell level and in clinical settings, due to significant distribution shifts between preclinical models and real-world patient data. Existing approaches often rely on transfer learning from cell lines to target domains, but typically require access to target-domain data during training, which is frequently unavailable in practice.
resultsWe propose FourierDrug, a novel domain generalization framework for robust drug response prediction. Given gene expression profiles, the model performs Fourier transformation to project features into the frequency domain and introduces an asymmetric attention mechanism that encourages drug-sensitive samples to form compact clusters while driving resistant samples to be more dispersed. This design facilitates the learning of domain-invariant yet task-relevant representations. Extensive experiments demonstrate that FourierDrug effectively leverages diverse source domains and generalizes well to unseen cancer types. Notably, when evaluated on single-cell and patient-level prediction tasks, our method-trained solely on in vitro cell line data without access to target-domain data-consistently outperforms or matches state-of-the-art approaches. AVAILABILITY AND IMPLEMENTATION: The source code and processed datasets are available at: https://github.com/hliulab/FourierDrug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.